1. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004;64:4040–4048.
2. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9:121–132.
3. Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, et al. Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res. 2003;9:5486–5492.
4. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A. 1999;96:6745–6750. [PubMed]
5. Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 2003;63:6–11.
6. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005;65:3146–3154.
7. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell. 2003;14:3208–3215.
8. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001;61:6885–6891. [PubMed] 9. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004;64:55–63. [PubMed] 10. Chen X, Cheung ST, So S, Fan ST, Barry C, et al. Gene expression patterns in human liver cancers. Mol Biol Cell. 2002;13:1929–1939. [PMC free article] [PubMed] 11. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790–13795. [PubMed] 12. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511. [PubMed]
13. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234–7242.
14. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745–1757. [PubMed] 15. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2001;98:1176–1181. [PubMed] 16. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003;162:1151–1162. [PubMed] 17. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002;1:203–209. [PubMed]
18. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, et al. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 2003;3:31.
19. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A. 2001;98:15044–15049. [PubMed]
20. Mazumder A, Wang Y. Gene-expression signatures in oncology diagnostics. Pharmacogenomics. 2006;7:1167–1173.
21. Xu L, Geman D, Winslow RL. Large-scale integration of cancer microarray data identifies a robust common cancer signature. BMC Bioinformatics. 2007;8:275. [PMC free article] [PubMed]
22. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A. 2004;101:9309–9314.
23. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005;4:1686–1696.
24. Warburg O. The metabolism of tumors; In: Smith R, editor. New York, NY: 1930.
25. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877–1881. [PMC free article] [PubMed] 26. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer. 2000;83:156–163. [PMC free article] [PubMed] 27. Yin XM. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene. 2006;369:7–19. [PubMed] 28. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, et al. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem. 2001;276:3149–3157. [PubMed]
29. Krajewska M, Zapata JM, Meinhold-Heerlein I, Hedayat H, Monks A, et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia. 2002;4:129–140.
30. Behrens P, Jeske W, Wernert N, Wellmann A. Downregulation of clusterin expression in testicular germ cell tumours. Pathobiology. 2001;69:19–23.
31. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol. 2006;168:574–584. [PubMed]
32. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer. 2004;108:23–30.
33. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, et al. Expression of clusterin in human pancreatic cancer. Pancreas. 2002;25:234–238. [PubMed]
34. Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, et al. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol. 2003;9:650–654.
35. Andersen CL, Schepeler T, Thorsen K, Birkenkamp-Demtroder K, Mansilla F, et al. Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007
36. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, et al. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 2004;64:3126–3136.
37. Bhattacharya B, Miura T, Brandenberger R, Mejido J, Luo Y, et al. Gene expression in human embryonic stem cell lines: unique molecular signature. Blood. 2004;103:2956–2964.
38. Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A. 2003;100:13350–13355.
39. Chaparro J, Reeds DN, Wen W, Xueping E, Klein S, et al. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism. 2005;54:561–567.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. [PubMed] 41. Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 2006;66:820–827. [PubMed]
42. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, et al. Deciphering cellular states of innate tumor drug responses. Genome Biol. 2006;7:R19.
43. Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, et al. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology. 2006;131:925–933. [PMC free article] [PubMed]
44. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res. 2002;62:233–240.
45. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006;24:274–287. [PubMed]
46. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene. 2004;23:2484–2498.
47. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics. 2005;21:4205–4208. [PubMed]
48. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005;167:1763–1775.
49. Storz MN, van de Rijn M, Kim YH, Mraz-Gernhard S, Hoppe RT, et al. Gene expression profiles of cutaneous B cell lymphoma. J Invest Dermatol. 2003;120:865–870.
50. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21:6848–6857. [PubMed] 51. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8:393–406. [PubMed]
52. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A. 2004;101:811–816.
53. Skotheim RI, Lind GE, Monni O, Nesland JM, Abeler VM, et al. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res. 2005;65:5588–5598. [PubMed] 54. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005;166:1827–1840. [PubMed]
55. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril. 2004;82:639–649.
56. Yoon SS, Segal NH, Park PJ, Detwiller KY, Fernando NT, et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 2006;135:282–290. [PubMed]
57. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001;98:15149–15154.